Select Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 19, 2026

Upside

– $IRON +52% (Phase 3 APOLLO trial met all primary and secondary endpoints in erythropoietic protoporphyria)

– $AAME +41% (long-delayed 2025 annual report was filed, showing a return to annual profitability)

– $XLAB +24% (extends rally after securing an $8.2M AI-server order)

– $TCRT +20% (extends volatile rally tied to a proposed acquisition and financing of up to $350M)

– $MEDS +15% (extends rally after outlining peptide-compounding expansion and licensing a direct-to-consumer GLP-1 platform)

– $CLF +11% (Q3 profit and EBITDA beat expectations, Q4 EBITDA was guided higher and 2027 EBITDA is expected to exceed $4B)

– $NBIS +7.5%, $CRWV +7.7%, $BE +5.2%, $SMCI +4.1%, $IREN +5.9% (AI-infrastructure names rebound from last week’s financing-driven selloff as Treasury yields ease)

– $CRDO +4.7%, $TER +5.1%, $LRCX +4.6%, $AMD +3.7%, $MU +3.7%, $AVGO +3.1% (chip names rebound from last week’s AI-led selloff ahead of key sector earnings)

– $INTC +4.3% (JPMorgan upgrades to Neutral from Underweight as confidence in the turnaround improves)

– $VAI +4.0% (agrees to acquire an 18MW Ohio computing center)

– $DDOG +3.9% (Bernstein upgrades to Outperform and sharply raises its price target on stronger AI-consumption trends)

Downside

– $ACTU -9.1% (files to sell 40M shares with 20M warrants)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 12, 2026

Upside

– $GIXI +135.0% (autonomous robots begin delivering blood and bone marrow at a major hospital, expanding an existing chemotherapy-logistics deployment)

– $CCC +10.5% (GTCR and Elliott are reportedly in advanced acquisition talks, with a deal potentially coming this week)

– $MEDS +7.0% (Humana adds the ChemoFx gynecologic-cancer assay to a Medicaid coverage policy)

– $IREN +5.5% (Anthropic is reportedly the previously undisclosed customer behind a multiyear AI-cloud services agreement)

– $BIIB +2.5% (JPMorgan upgrades to Overweight, citing an increasingly compelling clinical-catalyst path)

– $BFLY +1.5% (Canaccord initiates coverage with a Buy rating)

Downside

– $WFF -15.5% (gives back part of Friday’s nearly 500% speculative surge, with no fresh company catalyst identified)

– $QUCY -13.5% (launches an at-the-market equity program allowing up to $100 million of share sales)

– $MU -2.5%, $MRVL -2.0%, $INTC -1.5% (chip stocks weaken as advanced-memory competition and concerns over AI spending weigh on the sector)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 1, 2026

Upside

– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)

– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)

– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)

– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)

– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)

– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)

– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)

– $IBM +5.7% (unveils a self-hosted enterprise AI model)

– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)

– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)

– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)

– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)

– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)

– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)

– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)

Downside

– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)

– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)

– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)

– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)

– $BGIN -10% (slides following first-half results)

– $IVA -10% (extends weakness following unaudited first-half results and corporate update)

– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)

– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 28, 2026

Upside

– $KOD +60% (pivotal Phase 3 DAYBREAK wet-AMD trial met its primary noninferiority endpoints, with most patients reaching a 24-week dosing interval)

– $ARAY +39% (agrees to explore integrating Samsung NeuroLogica volumetric imaging technology with the CyberKnife platform)

– $MEDS +28% (launches a GLP-1 care app offering telehealth consultations and access to branded medications)

– $WBUY +27% (first-half revenue nearly doubled, gross profit rose 132% and the net loss narrowed)

– $MTEK +21% (receives a record $10 million order for advanced video systems on next-generation airborne defense platforms)

– $AMPX +12% (wins a Defense Department grant of up to $75 million for domestic high-energy-density battery production, with about $22 million obligated initially)

– $SRFM +7.1% (selected as a participating airspace user in the FAA SMART program)

– $NTES +4.6% (no clear fresh catalyst identified; unusually large, liquid premarket move)

– $SM +2.6%, FRO +2.9%, APA +2.5%, OXY +1.7%, XOM +1.5%, CVX +1.5% (energy names rise as crude advances after the US rejected Iran’s conditions for reopening the Strait of Hormuz)

– $CF +2.4% (Rothschild Redburn upgrades to Neutral from Sell, citing a tighter nitrogen-market outlook)

Downside

– $GFI -13% (confirms a rejected A$27-per-share cash-and-stock proposal for Northern Star that would leave target holders owning about 33% of the combined company)

– $MNOV -12% (Phase 2 trial failed to show a statistically significant triglyceride benefit versus placebo at Week 24)

– $AU -5.6%, AG -4.5%, CDE -5.1%, HL -4.9%, EGO -4.6%, NEM -4.0% (precious-metals miners fall as gold and silver tumble on a stronger dollar, rising yields and increased Fed rate-hike expectations)

– $FCX -3.3%, SCCO -3.4%, HBM -3.8% (base-metal miners fall as the stronger dollar and rising yields pressure commodity prices)

– $META -2.7% (pulls back after last week’s sharp AI-led rally as rising Treasury yields pressure megacap growth stocks)

– $BE -2.6%, GLW -2.0%, MOD -3.0% (data-center infrastructure names retreat in the higher-yield risk-off tape)

– $CRCL -2.0% (crypto-linked shares weaken as Bitcoin falls about 2%)

– $TTMI -1.8%, CRDO -2.5%, SKHY -3.3%, INTC -2.4%, ARM -2.1%, SNDK -2.7% (high-beta chip and memory names retreat as oil-driven inflation fears lift Treasury yields and pressure the Nasdaq tape)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 18, 2026

Upside

– $MEDS +30% (litigation settlement is expected to extinguish about $19 million of liabilities and retire 364,099 shares)

– $USDE +17%, $PURR +7.0%, $MSTR +2.8%, $HOOD +2.2% (crypto and tokenization-linked stocks rise as Bitcoin rallies and regulators grant temporary relief for tokenized U.S. stock trading)

– $STUB +6.0% (Citi upgrades to Buy from Neutral)

– $GOOGL +2.0%, $GOOG +1.9% (no clear fresh company-specific catalyst identified; unusually strong megacap premarket outperformance)

– $ETSY +1.1% (BTIG upgrades to Buy, citing improved valuation, positive demand tracking and a better cost structure)

Downside

– $XENE -22% (pauses new enrollment in Phase 3 depression trials after a liver-related safety event, overshadowing the focal-seizure NDA submission)

– $AEMD -9.9% (reverses part of the prior-day merger-driven surge; existing holders are expected to own about 4.75% of the combined company)

– $ARRY -4.2% (UBS downgrades to Neutral and flags growing cash preferred-dividend obligations that could pressure free cash flow)

– $NFLX -3.2% (Wells Fargo downgrades to Underweight, citing weakening engagement and a softer original-content slate)

– $NUE -2.3%, STLD -2.1% (steelmakers fall after STLD’s Q3 earnings outlook missed expectations)

– $DLR -2.0% (rate-sensitive stocks fall as Treasury yields edge higher)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 17, 2026

Upside

– $AEMD +403% (merger agreement with North Immunology adds an IL-13 x IL-18 bispecific-antibody program for atopic dermatitis)

– $GNRC +30% (Amazon supply agreement includes $2.4B of backup-generator deliveries expected during 2027-2028)

– $VEEA +30% (non-binding combination term sheet with NovaGen targets a $750M AI-health platform)

– $DTSS +12% (strategic cooperation expands into AI-powered elderly-care robots in China)

– $MEDS +12% (Helomics acquisition expands its cancer-diagnostics and precision-oncology platform)

– $VICR +12% (licenses its vertical power-delivery technology to a leading AI OEM)

– $NBIS +9.0% (reported AI-compute price increases signal stronger pricing power amid constrained capacity)

– $IREN +5.5%, CIFR +6.3% (AI-compute peers gain on the pricing-power read-through from NBIS)

– $APLD +5.8%, HUT +5.0%, WULF +4.7% (Wells Fargo initiates the data-center infrastructure names at Overweight)

– $NOK +5.0% (expands its Microsoft partnership by integrating network-automation data tools with Microsoft Fabric)

– $BE +4.5%, $GEV +3.3% (data-center power names gain as the Amazon-GNRC agreement reinforces hyperscaler power demand)

– LCID +4.2% (partners with Bolt to deploy at least 25,000 Level 4 autonomous vehicles across Europe)

– QGEN +3.5% (traders circulating German press report saying Qiagen attracts interest from KKR, Advent, TPG)

– GLW +3.7%, ANET ($ANET) +2.7%, CIEN +3.2% (AI networking and optical names rise as compute pricing points to continued infrastructure tightness)

– MRVL ($MRVL) +3.5%, LRCX +3.6%, INTC +3.2%, TER +3.6%, AMAT +3.2%, KLAC +3.2% (semiconductors rebound with technology shares after the Fed decision clears a major policy-event overhang)

Downside

– LGVN -49% (Phase 2b ELPIS II trial in hypoplastic left heart syndrome missed its primary efficacy endpoint)

– DLXY -45% (reverses sharply after a non-binding LOI covering up to a 48% interest in a Kazakhstan oil-field project)

– FLNC -22% (cuts FY guidance as supply-chain issues and delays ramping its Houston manufacturing facility drive a much larger expected loss)

– S -3.9% (no clear fresh catalyst identified; notable liquid cybersecurity move)

– BDX -3.5% (no clear fresh catalyst identified; unusually large premarket move in the medical-device name)

– LEN ($LEN) -1.3% (quarter missed and forward guidance disappointed as affordability pressure continued to weigh on homebuilding demand)

Source: Trade The News